Beyond
the Biobucks

What became of China's biggest pharma licensing deals, and what risks buyers took on.

Terminal access

The Series

One deal per post.
What happened next.

Analysis

50 deals,
one at a time.

One star per deal, placed on the day it was signed and on the floor of the stage the drug had reached. Pick a star: its line shows how far the buyer has taken the drug since.

2026-11-17

Rewinds the chart and the comparison to what was public on that day. The deal reading below the chart stays at today.

50 of 50
PRECLINICALPHASE 1PHASE 2PHASE 3FILEDAPPROVED2017201820192020202120222023202420252026
Compareby

Counts the deals that pass the filters above. n = deals behind each bar; faded bars rest on fewer than three. Tracked deals only: a small sample, no statistical test.

Jiangsu Hengrui → GSK · HRS-9821 + options on 11 programmes · signed 2025 · $12.50B announced · Phase 1 → Phase 1

Jiangsu Hengrui → GSK

ACTIVEHRS-9821 + options on 11 programmes · signed 2025-07-28 · 16 months ago

$500M upfront for one COPD asset and options on eleven more; the $12B assumes every option is taken and every milestone met.

The money

Announced$12.50B
Upfront$500M · 4.0%
Risk-adjusted$2.13B
Confirmed paidn/d
  1. Pre
  2. P12025 · now
  3. P2
  4. P3
  5. Filed
  6. Appr.
How to read these figures

n/d: no payment found in a public source, which is unknown and not zero. Median upfront share of the 19 deals signed at Phase 1: 5.3%.

The risk-adjusted value weights the milestones by published success rates (9% chance of approval from Phase 1), with an assumed split between development and sales milestones. It is a model, not a reported figure.

Stage bar: the year marks the stage at signing, the orange step the stage reached today.

Territory: Worldwide excluding Greater China.

Comparable deals: 4 at Phase 1, outside oncology

This upfront, $500M, ranks 1 of 5. Median $185M, from $21.5M to $500M.

Same area and same stage at signing, tracked deals only: a short list, not a benchmark.

rNPV calculator: your assumptions

Probability of approval from Phase 1: 9.3% (BIO 2011-2020). Every other field is your assumption; the values filled in are unsourced defaults. Peak sales are those of the licensed territory: Worldwide excluding Greater China. Royalties are not counted.

For scale, reported sales of medicines already sold in the disease, worldwide and in all their indications: Breztri $1.20B in 2025.

The drug

  • small molecule + platform
  • PDE3/4
  • COPD
Market context: 1 of 1 disease

COPD. 3,400,000 deaths a year (World, 2023; World Health Organization).

Already sold in it: Breztri $1.20B. Reported 2025 sales, worldwide, all uses of each medicine.

Patient counts and reported sales from public documents. Context, not a market size.

No other tracked deal shares this target (50 deals tracked).

Outside the tracker: 18 on PDE3A

10 more on Open Targets, release 26.09, read 2026-11-17. Highest stage in any indication. A secondary source: recent or China-only programmes can be missing.

Outside the tracker: 28 on PDE4B

20 more on Open Targets, release 26.09, read 2026-11-17. Highest stage in any indication. A secondary source: recent or China-only programmes can be missing.

The trials

0
registered
0
running
0
completed
0
stopped
Phase 10
Phase 20
Phase 30

0 started by GSK since signing. Registry status only, no results.

No results posted in the registry for these trials yet.

Points to check · 2

The upfront is 4.0% of the announced value.

No payment found in a public source, 16 months after signing.

The parties

-7%
seller's share price since signing
Company profiles

Jiangsu Hengrui. 5 tracked deals, $22.57B announced, 0 ended or cut back. Own trials: 44% in oncology, of 694 as lead sponsor. Profile →

GSK. 4 tracked deals, $16.79B announced, 0 ended or cut back. Own trials: 13% in oncology, of 3378 as lead sponsor. Profile →

Own trials: ClinicalTrials.gov, read 2026-11-17. Tracked deals only.

Sources

No annual figures in US dollars for GSK before signing.

Jiangsu Hengrui: 600276.SS, 2025-06 to 2026-11 (Yahoo Finance, secondary source).

Deal file: company releases: 1, trade press: 1. Figures pending review.

Full record in the terminal →

Read on 2026-11-17. The checks are facts from public sources, not a rating and not investment advice. Figures pending review.

The Terminal

The headline number
is a promise.

When a Chinese biotech licenses a drug to a Western buyer, the press release leads with one figure in the billions. Most of it is conditional. The terminal follows each deal after the signature: payments confirmed by a public source, trials started, programmes dropped, rights returned. A date slider rewinds every deal to what was public on that day.

50
deals tracked
$126.4B
announced
$3.7B
confirmed paid in public sources
12
ended or cut back
Open the terminal →

Figures pending review

Method

How the numbers
are built.

Announced
The upfront plus every milestone the announcement mentions. It is the ceiling of the deal, reached only if every trial, filing and sales target succeeds.
Confirmed paid
Payments that a public document says were made or received: a regulatory filing, a stock-exchange announcement, a company release. Without such a document the deal shows n/d, never zero.
Status
Active, partly returned or terminated. It is read from the dated events of each deal: a termination, rights handed back, a programme dropped.
As of
The terminal can rewind to any month. An event counts from the date of the source that reports it, so a payment made in 2021 and disclosed in a 2023 filing appears in 2023.
Market context
For each disease, two public figures: how many people it concerns, and the reported yearly sales of medicines already sold in it. Market-research estimates are left out because they cannot be checked.
Models
Two figures are computed, not reported: the risk-adjusted value, and the rNPV calculator, which runs on assumptions you type. Both are marked as models so they are never read as money paid.
Sources
Public documents only. Filings, company releases and trial registries come first; trade press is used as a secondary source and labelled as such.
Limits
Each deal is entered by hand, one file per deal. The files are still waiting for a second review, so figures may change. This is descriptive research, not investment advice.